Compare CARS & SLBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CARS | SLBT |
|---|---|---|
| Founded | 1998 | N/A |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Motor Vehicles | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 546.6M | 644.9M |
| IPO Year | 2017 | 2025 |
| Metric | CARS | SLBT |
|---|---|---|
| Price | $13.36 | $0.91 |
| Analyst Decision | Hold | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $13.33 | N/A |
| AVG Volume (30 Days) | ★ 717.4K | 38.2K |
| Earning Date | 11-05-2026 | 10-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $723,239,000.00 | N/A |
| Revenue This Year | $0.77 | N/A |
| Revenue Next Year | $2.16 | N/A |
| P/E Ratio | $38.64 | ★ N/A |
| Revenue Growth | ★ 0.57 | N/A |
| 52 Week Low | $7.40 | $1.02 |
| 52 Week High | $13.69 | $6.25 |
| Indicator | CARS | SLBT |
|---|---|---|
| Relative Strength Index (RSI) | 75.03 | 26.53 |
| Support Level | $10.70 | N/A |
| Resistance Level | N/A | $1.75 |
| Average True Range (ATR) | 0.53 | 0.17 |
| MACD | 0.34 | -0.01 |
| Stochastic Oscillator | 82.53 | 25.12 |
Cars.com Inc is an audience-powered and data-driven technology platform that simplifies buying and selling cars. The flagship Cars.com marketplace connects consumers to dealerships across the U.S., powering the car-buying experience with artificial intelligence (AI) shopping tools, vehicle reviews and content. Its ecosystem of products enables dealers and OEMs to sell more cars by leveraging the marketplace, dealer websites, trade and appraisal tools and proprietary in-market media solutions. The platform provides shoppers with data, resources and digital tools to make informed buying decisions and connect with automotive retailers. The Company also provides dealerships and OEMs with solutions and data-driven intelligence to reach and influence its 26 million monthly shoppers.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.